DexCom/$DXCM

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Ticker

$DXCM
Primary listing

Industry

Health Care Equipment & Supplies

Employees

10,250

ISIN

US2521311074

DexCom Metrics

BasicAdvanced
$32B
60.81
$1.33
1.50
-

What the Analysts think about DexCom

Analyst ratings (Buy, Hold, Sell) for DexCom stock.

Bulls say / Bears say

DexCom reported a 27% year-over-year revenue increase in Q3 2023, reaching $975 million, and raised its full-year revenue guidance to approximately $3.575 to $3.6 billion. (benzinga.com)
The company announced a $500 million share repurchase program, indicating confidence in its financial position and future growth prospects. (benzinga.com)
DexCom's G7 Continuous Glucose Monitoring System received FDA approval in December 2022, with U.S. availability beginning in February 2023, potentially expanding its market share. (wikipedia.org)
In October 2023, DexCom's stock hit a new 52-week low, trading at $77.73, amid concerns over the FDA's establishment of a Digital Health Advisory Committee, which could lead to increased regulatory scrutiny. (benzinga.com)
The rising popularity of weight loss drugs in 2023 has put pressure on DexCom's stock, as these medications may reduce the need for continuous glucose monitoring devices. (benzinga.com)
DexCom received a warning letter from the FDA following inspections of its two key manufacturing facilities, which could impact production and sales. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

DexCom Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DexCom Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DXCM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs